PHAT: Phathom Pharmaceuticals, Inc.
About
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Current Value
$9.381 Year Return
Current Value
$9.381 Year Return
Key Details
Market Cap
$640.70M
P/E Ratio
-1.65
1Y Stock Return
29.96%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
-3.4
Strategies that include PHAT
Stock's related to PHAT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALDX | 30.88% | $294.18M | +102.46% | 0.00% |
| OCUL | 29.93% | $1.40B | +307.31% | 0.00% |
| SPNS | 29.78% | $1.52B | +6.33% | 2.13% |
| BIO | 26.59% | $8.98B | +4.73% | 0.00% |
| AMED | 26.36% | $2.95B | -3.95% | 0.00% |
| LYTS | 26.21% | $604.82M | +53.68% | 1.00% |
| RARE | 26.06% | $4.17B | +16.19% | 0.00% |
| NNDM | 25.93% | $458.21M | -13.64% | 0.00% |
| PSEC | 25.67% | - | - | 15.48% |
| NVCR | 25.66% | $1.78B | +34.75% | 0.00% |
| PAX | 25.58% | $1.83B | -15.48% | 8.96% |
| PCOR | 25.31% | $10.41B | +26.77% | 0.00% |
| KNSL | 24.96% | $10.93B | +29.38% | 0.13% |
| CDZI | 24.88% | $243.60M | +7.64% | 0.00% |
| CRON | 24.86% | $776.06M | 0.00% | 0.00% |
| TCTM | 24.86% | $8.10M | -42.99% | 0.00% |
| VERI | 24.72% | $111.67M | +35.81% | 0.00% |
| RXRX | 24.68% | $1.80B | -4.13% | 0.00% |
| NTLA | 24.52% | $1.44B | -50.35% | 0.00% |
| OPTN | 24.40% | $51.10M | -72.23% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLB | -<0.01% | $929.61M | +8.55% | 0.20% |
| NR | -0.02% | $620.19M | +0.14% | 0.00% |
| RDN | -0.02% | $5.04B | +32.94% | 2.84% |
| FDS | -0.03% | $18.29B | +5.24% | 0.84% |
| GAN | -0.03% | $83.39M | +21.19% | 0.00% |
| SRAD | -0.03% | $5.18B | +75.20% | 0.00% |
| GOOG | -0.04% | $2.20T | +29.55% | 0.22% |
| CMRE | -0.05% | $1.73B | +53.76% | 3.17% |
| RS | -0.07% | $16.72B | +15.56% | 1.05% |
| BVN | 0.08% | $3.16B | +37.49% | 0.00% |
| IDCC | 0.11% | $4.64B | +83.82% | 0.90% |
| HTLD | 0.12% | $962.37M | -5.03% | 0.65% |
| MDLZ | -0.12% | $85.41B | -10.00% | 2.73% |
| CB | 0.13% | $114.43B | +26.00% | 1.24% |
| SMR | 0.13% | $2.73B | +989.52% | 0.00% |
| CSCO | 0.14% | $227.24B | +19.27% | 2.80% |
| CTVA | -0.14% | $40.03B | +25.87% | 1.11% |
| EFR | 0.15% | $1.42B | -14.34% | 0.00% |
| T | -0.15% | $163.09B | +40.40% | 4.87% |
| FVRR | 0.15% | $1.07B | +33.94% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTCT | -31.63% | $42.61M | +353.33% | 0.00% |
| DBX | -25.04% | $8.26B | -4.51% | 0.00% |
| YELP | -19.69% | $2.36B | -21.93% | 0.00% |
| CHD | -17.87% | $27.18B | +19.50% | 1.03% |
| USM | -15.56% | $5.35B | +41.82% | 0.00% |
| MNOV | -14.29% | $93.19M | +2.15% | 0.00% |
| PG | -14.29% | $402.15B | +14.14% | 2.33% |
| THS | -14.10% | $1.72B | -17.36% | 0.00% |
| ADBE | -13.32% | $219.93B | -18.23% | 0.00% |
| TDS | -12.89% | $3.56B | +63.43% | 1.43% |
| WLKP | -12.72% | $796.39M | +4.00% | 8.34% |
| COR | -12.16% | $47.48B | +21.20% | 0.86% |
| SHEL | -12.11% | $205.19B | -1.07% | 4.20% |
| VZ | -12.00% | $176.51B | +12.56% | 6.37% |
| TRUP | -11.60% | $2.24B | +97.76% | 0.00% |
| FTNT | -11.59% | $69.59B | +72.67% | 0.00% |
| LULU | -11.19% | $37.06B | -29.86% | 0.00% |
| KHC | -10.70% | $36.98B | -10.45% | 5.23% |
| LNG | -10.01% | $49.37B | +24.99% | 0.82% |
| PEP | -10.01% | $215.02B | -6.60% | 3.35% |
ETF's related to PHAT
News
SeekingAlpha
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsEric Sciorilli - Head of...
Yahoo
Phathom Pharmaceuticals Inc (PHAT) reports a significant revenue increase and strong market penetration for VOQUEZNA, despite ongoing financial challenges.
Yahoo
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 15.92% and 30.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NE
Yahoo
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagem
Yahoo
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.